National and Kapodistrian University of Athens
Συσχέτιση του βιοχημικού παράγοντα ADAM 12 στο πρώτο τρίμηνο της κύησης με υπέρταση και καθυστέρηση της ενδομήτριας ανάπτυξης
Abstract
dc:descriptionPurpose: Delineate whereas ADAM-12 levels at first trimester of pregnancmay be used as marker for hypertension-preeclampsia and IUGR.Materials & Methods: It is a case control study. Serum ADAM 12 of women presenting for routine assessment of risk for chromosomal abnormalities at 11+0 to13+6 weeks of gestation was measured. The study group comprised of 98 pregnancies that subsequently developed gestational hypertension(PIH) orpreeclamsia(PE) or small for gestational age fetuses(SGA), and were compared to 100 uncomplicated pregnancies.Results: There was no statistically significant difference of mean log MoM of ADAM12 between control group and the group that consisted of all women withcomplicated pregnancy (PE, PIH and SGA). ADAM12 levels in women who developed PE during pregnancy were significantly lower than in women of controlgroup (mean log MoM: 0.109 vs 0.008, p=0.010). Similarly, ADAM12 levels in women who developed PE and/or PIH were significantly lower than in women ofcontrol group (mean log MoM: 0.066 vs 0.008, p=0.015). There was no significant difference of ADAM12 levels between controls and pregnancies with SGAfetuses.Conclusion: Maternal serum levels of ADAM-12 at the first trimester are significantly lower in women who later develop preeclampsia and hypertantion compared with women with uncomplicated pregnancies.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2015
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kasimis, Charilaos
- Κασίμης, Χαρίλαος
Subjects
dc:subject × 14Rights
dc:rights- Statement dc:rights
-
- BY_NC_SA
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/42421